PACT - Public Activities Coordination Tool

PACT - Public Activities Coordination Tool

PACT - Public Activities Coordination Tool

The public activities coordination tool (PACT) provides an overview of the substance-specific activities that authorities are working on under REACH and the CLP Regulation. These activities are being carried out in line with ECHA’s Integrated Regulatory Strategy.

PACT provides up-to-date information on the activities planned, ongoing or completed by ECHA and/or MSCAs for a given substance in the following areas:

  • Data generation and assessment – dossier evaluation, substance evaluation, informal hazard assessment (PBT/vPvB/ED).
  • Assessment of regulatory needs (ARN).
  • Regulatory risk management – harmonised classification and labelling (CLH) , SVHC identification, recommendations for inclusion in the Authorisation List, restriction.

A summary of all the substance-specific activities can be found under ‘Details’ for each entry.

(1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate

EC / List no: 214-619-0 CAS no: 1166-46-7
Data generation and assessment
ED - Endocrine disruptor assessment
ED 1
Authority
Germany
Status
Under development
Outcome
Under development (BPR)
Hazard assessment outcome document
Remarks
Biodical active substance
Concern
Endocrine disruption
Date of intention
29-Sep-2020
Date of hazard assessment
Latest update
03-Feb-2021
More information View
Regulatory risk management
CLH - Harmonised classification and labelling
CLH 1
Status
Opinion Adopted
Date of intention
17-Dec-2013
Withdrawal date
Submitter
Germany
Proposed harmonised classification by the dossier submitter
Acute Tox. 4, H332
Carc. 2, H351
STOT SE 2, H371
Aquatic Acute 1, H400
Aquatic Acute 1, M-factor=100
Aquatic Chronic 1, H410
Aquatic Chronic 1, M-factor=100
Remarks
Date of opinion
16-Sep-2016
RAC Opinion
Latest update
25-Jul-2022
More information View

List entry date: 28-Feb-2018

Export search results to:

EU Privacy Disclaimer

This website uses cookies to ensure you get the best experience on our websites.